Management Strategies for Recurrent Endometrial Cancer

References

• Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354–361.
   PubMedGoogle Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Duong LM, Wilson RJ, Ajani UA, et al.. Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Womens Health (Larchmt). 2011;20(8):1157–1163.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Surveillance, Epidemiology, and End Rsults Program. Cancer stat facts: Uterine cancer. Accessed from December 28, 2017.https://seer.cancer.gov/statfacts/html/corp.html.
   Google Scholar
• Bokman J. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17.
   PubMed Web of Science ®Google Scholar
• Hamilton C, Cheung M, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646.
   PubMed Web of Science ®Google Scholar
• Xu Y, Burmeister C, Hanna RK, et al.. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer. 2016;26(6):1137–1142.
   PubMed Web of Science ®Google Scholar
• Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol. 1984;17(1):85.
   PubMed Web of Science ®Google Scholar
• Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101(3):520–529.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Uterine neoplasms (version 1.2018). Accessed from https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdfhttps://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Updated January 2018. April 29, 2018.
   Google Scholar
• Hunn J, Tenney ME, Tergas AI, et al. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015;137(3):485–489.
   PubMed Web of Science ®Google Scholar
• Salani R, Khanna N, Frimer M, et al.. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncology (SGO) recommendations. Gynecol Oncol. 2017;146(1):3–10.
   PubMed Web of Science ®Google Scholar
• Frimer M, Hou JY, McAndrew TC, et al.. The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer. Reprod Sci. 2013;20(4):449–455.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, Van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89(2):201–209.
   PubMed Web of Science ®Google Scholar
• Huh WK, Jm S Jr, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007;17(4):886–889.
   PubMed Web of Science ®Google Scholar
• Curran WJ, Whittington R, Peters A, et al.. Vaginal recurrences of endometrial carcinoma: the prognostic value of staging by a primary vaginal carcinoma system. Int J Radiat Oncol Biol Phys. 1988;15(4):803–808.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa B, Badzio A, Recurrent JJ. Endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(2):405–413.
   PubMed Web of Science ®Google Scholar
• Llewelyn M, Taylor A. Re-irradiation of cervical and endometrial cancer. Curr Opin Oncol. 2017;29(5):343–350.
   PubMed Web of Science ®Google Scholar
• Barakat RR, Goldman NA, Patel DA, et al.. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999;75(1):99–102.
   PubMed Web of Science ®Google Scholar
• Morris M, Alvarez RD, Kinney WK, et al.. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol. 1996;60(2):288–291.
   PubMed Web of Science ®Google Scholar
• Khoury-Collado F, Einstein MH, Bochner BH, et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol. 2012;124(1):42–47.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Imesch P, Fink D, et al.. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients. Int J Gynecol Cancer. 2016;26(4):716–721.
   PubMed Web of Science ®Google Scholar
• Seagle BL, Dayno M, Strohl AE, et al.. Survival after pelvic exenteration for uterine malignancy: a national cancer data base study. Gynecol Oncol. 2016;143(3):472–478.
   PubMed Web of Science ®Google Scholar
• Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–823.
   PubMed Web of Science ®Google Scholar
• Bosse T, Peters EE, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51(13):1742–1750.
   PubMed Web of Science ®Google Scholar
• Hasan S, Ricco A, Jenkins K, et al. Survival and control prognosticators of recurrent gynecological malignancies of the pelvis and para-aortic region treated with stereotactic body radiation therapy. Front Oncol. 2016;6:249.
   PubMed Web of Science ®Google Scholar
• Ho JC, Allen PK, Jhingran A, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015;139(1):40–46.
   PubMed Web of Science ®Google Scholar
• Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118(1):14–18. .
   PubMed Web of Science ®Google Scholar
• Turan T, Tasci T, Karalok A, et al. Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer. 2015;25(9):1623–1632.
   PubMed Web of Science ®Google Scholar
• Papadia A, Bellati F, Ditto A, et al. Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol. 2015;22(13):4204–4210.
   PubMed Web of Science ®Google Scholar
• Awtrey CS, Cadungog MG, Leitao MM, et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol. 2006;102(3):480–488.
   PubMed Web of Science ®Google Scholar
• Zanfagnin V, Ferrero A, Biglia N, et al. The role of surgery in recurrent endometrial cancer. Expert Rev Anticancer Ther. 2016;16(7):741–750.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, DiSaia PJ, et al.. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 1994;12(7):1408–1414.
   PubMed Web of Science ®Google Scholar
• Van Wijk FH, Aapro MS, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC gynaecological cancer group. Ann Oncol. 2003;14(3):441–448.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(19):3902–3908.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a gynecologic oncology group study. Ann Oncol. 2004;15(8):1173–1178.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. JCO. 2004;22(11):2159–2166.
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al.. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;125:771–773.
   Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol. 2011;29(16):2259–2265.
   PubMed Web of Science ®Google Scholar
• Simpkins F, Drake R, Escobar PF, et al.. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol. 2015;136(2):240–245.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci VL, Dizon DS, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage IV or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015;33(15 suppl;abstract) 5500.
   Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Colombo N, et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial. J Clin Oncol. 2015; 33(15 suppl;abstract) 5502.
   Web of Science ®Google Scholar
• Fleming GF. Second-line therapy for endometrial cancer: the need for better options. J Clin Oncol. 2015;33(31):3535–3540.
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/intergroup study. Gynecol Oncol. 2013;131(3):567–573.
   PubMed Web of Science ®Google Scholar
• Lissoni A, Zanetta G, Losa G, et al.. II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996;7(8):861–863.
   PubMed Web of Science ®Google Scholar
• Lincoln S, Ja B, Rb L, et al.. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2003;88(3):277–281.
   PubMed Web of Science ®Google Scholar
• Aa G, Ja B, Nolte S, et al.. Gynecologic Oncology Group. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the gynecologic oncology group. Gynecol Oncol. 2008;111(1):22–26.
   PubMed Web of Science ®Google Scholar
• Di Legge A, Trivellizzi IN, Moruzzi MC, et al.. 2 trial of nonpegylated doxorubicin (myocet) as second-line treatment in advanced or recurrent endometrial cancer. Int J Gynecol Cancer. 2011;21(8):1446–1451.
   PubMed Web of Science ®Google Scholar
• Makker V, Hensley ML, Zhou Q, et al.. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: memorial sloan-kettering cancer center experience from 1995 to 2009. Int J Gynecol Cancer. 2013;23(5):929–934.
   PubMed Web of Science ®Google Scholar
• Fm M, Ja B, Sorosky J, et al.. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study. J Clin Oncol. 2002;20(9):2360–2364.
   PubMed Web of Science ®Google Scholar
• Hd H, Ja B, Sorosky J, et al.. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2005;98(2):294–298.
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Homesley HD, et al.. II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A gynecologic oncology group study. Cancer. 1994;73(5):1453–1455.
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 1996;63(1):101–104.
   PubMed Web of Science ®Google Scholar
• Dh M, Ja B, Dunton C, et al.. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the gynecologic oncology group. Gynecol Oncol. 1999;75(3):473–475.
   PubMed Web of Science ®Google Scholar
• Pawinski A, Tumolo S, Hoesel G, et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC gynecological cancer cooperative group. Eur J Obstet Gynecol Reprod Biol. 1999;86(2):179–183.
   PubMed Web of Science ®Google Scholar
• Ds M, Ja B, Ss L, et al.. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2002;87(3):247–251.
   PubMed Web of Science ®Google Scholar
• Sc P, Ja B, Husseinzadeh N, et al.. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2002;84(2):241–244.
   PubMed Web of Science ®Google Scholar
• Grendys EC Jr, Blessing JA, Burger R, et al.. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology group study. Gynecol Oncol. 2005;98(2):249–253.
   PubMed Web of Science ®Google Scholar
• Pm F, Ja B, Kl M, et al.. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2006;103(2):523–526.
   PubMed Web of Science ®Google Scholar
• Homesley HD, Meltzer NP, Nieves L, et al.. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol. 2008;13(1):62–65.
   PubMed Web of Science ®Google Scholar
• Ds M, Ja B, Rd D, et al. A phase II evaluation of pemetrexed (alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the gynecologic oncology. Gynecol Oncol. 2009;115(3):443–446.
   PubMed Web of Science ®Google Scholar
• Tait DL, Blessing JA, Hoffman JS, et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011;121(1):118–121.
   PubMed Web of Science ®Google Scholar
• Ds D, Ja B, Ds M, et al.. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol. 2009;27(19):3104–3108.
   PubMed Web of Science ®Google Scholar
• McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing J, DiSaia PJ, et al.. Treatment of advanced or recurrent endometrial carcinoma with medroxyprogesterone acetate (MPA): a gynecologic oncology group study. Gynecol Oncol. 1985;20(2):250.
   Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol. 1999;17(6):1736–1744.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Vance R, Lambuth B, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer. 1987;60(8 Suppl):2104–2116.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Brady MF, Homesley HD, et al.. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001;19(2):364–367.
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 2003;90(1):64–69.
   PubMed Web of Science ®Google Scholar
• Covens AL, Filiaci V, Gersell D, et al.. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011;120(2):185–188.
   PubMed Web of Science ®Google Scholar
• Emons G, Gunthert A, Thiel FC, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the arbeitsgemeinschaft gynakologische onkologie. Gynecol Oncol. 2013;129(3):495–499.
   PubMed Web of Science ®Google Scholar
• Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. 1997;64(1):126–129.
   PubMed Web of Science ®Google Scholar
• Lhomme C, Vennin P, Callet N, et al. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol. 1999;75(2):187–193.
   PubMed Web of Science ®Google Scholar
• Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF, Gynecologic Oncology Group. Goserelin acetate as treatment for recurrent endometrial carcinoma: a gynecologic oncology group study. Am J Clin Oncol. 2002;25(6):557–560.
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, et al.. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2000;78(2):212–216.
   PubMed Web of Science ®Google Scholar
• Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the national cancer institute of canada clinical trials group. Int J Gynecol Cancer. 2004;14(4):650–658.
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Yeap BY, Weiner LM, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an eastern cooperative oncology group study (E4882). Am J Clin Oncol. 2001;24(1):43–46.
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(1):10–14.
   PubMed Web of Science ®Google Scholar
• Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(1):4–9.
   PubMed Web of Science ®Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–978.
   PubMed Web of Science ®Google Scholar
• Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13(24):7487–7495.
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a gynecologic oncology group study. Gynecol Oncol. 2007;105(2):508–516.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;127(3):538–543.
   PubMed Web of Science ®Google Scholar
• Moore KN, Sill MW, Tenney ME, et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: an NRG/gynecologic oncology group trial. Gynecol Oncol. 2015;138(3):513–518.
   PubMed Web of Science ®Google Scholar
• Makker V, Filiaci VL, Chen LM, et al. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study 0229N. Gynecol Oncol. 2015;138(1):24–29.
   PubMed Web of Science ®Google Scholar
• Bender D, Sill MW, Lankes HA, et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;138(3):507–512.
   PubMed Web of Science ®Google Scholar
• Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2013;129(1):22–27.
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California phase II consortia. Gynecol Oncol. 2010;117(1):37–40.
   PubMed Web of Science ®Google Scholar
• Castonguay V, Lheureux S, Welch S, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California consortia. Gynecol Oncol. 2014;134(2):274–280.
   PubMed Web of Science ®Google Scholar
• Powell MA, Sill MW, Goodfellow PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2014;135(1):38–43.
   PubMed Web of Science ®Google Scholar
• Dizon DS, Sill MW, Schilder JM, et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2014;135(3):441–445.
   PubMed Web of Science ®Google Scholar
• Vergote I, Teneriello M, Powell MA, et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol. 2013;31(15):suppl5520.
   Web of Science ®Google Scholar
• English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013;17(2):85–99.
   PubMed Web of Science ®Google Scholar
• Slomovitz B, Schmeler K, Miller D, et al. Phase II study of cetuximab (erbitux) in patients with progressive or recurrent endometrial cancer. Gynecol Oncol. 2010;110(Suppl):Abstract13.
   Google Scholar
• Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2010;116(1):15–20.
   PubMed Web of Science ®Google Scholar
• Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319–4325.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a gynecologic oncology group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127(2):345–350.
   PubMed Web of Science ®Google Scholar
• Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;JCO2017765966.
   PubMed Web of Science ®Google Scholar
• MacKay HJ, Levine DA, Bae-Jump VL, et al. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget. 2017;8(48):84579–84594.
   PubMedGoogle Scholar
• Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135(2):184–189.
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108(5):1021–1026.
   PubMed Web of Science ®Google Scholar
• Oza AM, Pignata S, Poveda A, et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33(31):3576–3582.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol. 2011;29(24):3278–3285.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013;108(9):1771–1777.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–5419.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2013;129(3):486–494.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Thaker PH, et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;138(1):30–35.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos P, Makker V, Barry WT, et al. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. JCO. 2014;32(15):5515.
   Web of Science ®Google Scholar
• Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–253.
   PubMed Web of Science ®Google Scholar
• Makker V, Recio FO, Ma L, et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016;122(22):3519–3528.
   PubMed Web of Science ®Google Scholar
• Heudel PE, Fabbro M, Roemer-Becuwe C, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br J Cancer. 2017;116(3):303–309.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132(3):585–592.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–936.
   PubMed Web of Science ®Google Scholar
• Mo Z, Liu J, Zhang Q, et al.. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett. 2016;12(2):944–950.
   PubMed Web of Science ®Google Scholar
• Makker V, Green AK, Wenham RM, et al.. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4 ( 19-017-0056-7. eCollection).
   PubMedGoogle Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al.. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–2541.
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco DW, Dutcus CE, et al. A phase ib/II trial of lenvatinib (LEN) plus pembrolizumab (pembro) in patients (pts) with endometrial carcinoma. J Clin Oncol. 2017;35(Supple):abstr 5598.
   Google Scholar
• Laskov I, Drudi L, Beauchamp MC, et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol. 2014;134(3):607–614.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi A, Kiyokawa T, Sato Y, et al.. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014;120(19):2986–2995.
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, et al.. Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol. 2010;116(1):92–98.
   PubMed Web of Science ®Google Scholar
• Schuler KM, Rambally BS, DiFurio MJ, et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2015;4(2):161–173.
   PubMed Web of Science ®Google Scholar
• Sivalingam VN, Kitson S, McVey R, et al. Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br J Cancer. 2016;114(3):281–289.
   PubMed Web of Science ®Google Scholar
• Soliman P. Phase II study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer. J Clin Oncol. 2016;34(Abstract):5506.
   Google Scholar
• Philip CA, Laskov I, Beauchamp MC, et al.. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017;17(1): 638–017-3639–0.
   PubMedGoogle Scholar
• Brown Jones M, Neuper C, Clayton A, et al. Rationale for folate receptor alpha targeted therapy in “high risk” endometrial carcinomas. Int J Cancer. 2008;123(7):1699–1703.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. NCI budget summary data.https://www.cancer.gov/about-nci/budget/fact-book/data/research-funding. Updated May 24, 2017. Accessed January 12, 2018.
   Google Scholar